0.3437
1.21%
-0.0042
Dopo l'orario di chiusura:
.34
-0.0037
-1.08%
Precedente Chiudi:
$0.3479
Aprire:
$0.348
Volume 24 ore:
26,558
Relative Volume:
0.05
Capitalizzazione di mercato:
$1.15M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+4.15%
1M Prestazione:
-20.99%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Entero Therapeutics Inc Stock (ENTO) Company Profile
Nome
Entero Therapeutics Inc
Settore
Industria
Telefono
561-589-7020
Indirizzo
777 YAMATO ROAD, BOCA RATON
Entero Therapeutics Inc Borsa (ENTO) Ultime notizie
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
EMCOR Group (NYSE:EME) Sets New 12-Month High at $402.91 - Defense World
Evolus (NASDAQ:EOLS) Trading Down 2.9% - Defense World
Health Beat: Hope for children with EoE - 69News WFMZ-TV
Emmaus Life Sciences director buys $800 in company stock By Investing.com - Investing.com UK
Debt-Free Multibagger Stock Hit 18 Consecutive Upper Circuits & 52-Week Highs: Will the Rally Come to a Halt? - Dalal Street Investment Journal
EMCOR Group (NYSE:EME) Hits New 1-Year High at $402.91 - MarketBeat
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
Entero Therapeutics faces Nasdaq delisting over share price - Investing.com
Entero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Canoo Inc (NASDAQ: GOEV) Could Pass $4.5 In One Year Stock Forecast - Stocks Register
Understanding ENTO stock ratios for better investment decisions - US Post News
Entero Therapeutics Secures Exclusive Technology License - Investing.com
Entero Therapeutics Secures Exclusive Technology License By Investing.com - Investing.com Canada
Entero Therapeutics signs letter of intent with Data Vault Holdings - TipRanks
Entero Therapeutics Signs Letter of Intent to License and - GlobeNewswire
Entero Therapeutics appoints new independent accountant - Investing.com India
Entero Therapeutics appoints new independent accountant - Investing.com
Entero Therapeutics appoints new independent accountant By Investing.com - Investing.com Canada
Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Up 666.0% in August - Defense World
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - GlobeNewswire
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - Yahoo Finance
Entero Therapeutics appoints new Audit Committee member - Investing.com India
Entero Therapeutics appoints new Audit Committee member - Investing.com
180 Life Sciences (NASDAQ:ATNF) Stock Quotes, Forecast and News Summary - Benzinga
Entero Therapeutics appoints new Audit Committee member By Investing.com - Investing.com UK
ENTO’s 2023 Market Dance: Down -90.00% – Time to Invest? - The InvestChronicle
Monitoring Entero Therapeutics Inc. (ENTO) after recent insider movements - Knox Daily
ENTO (Entero Therapeutics) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
Bone Biologics (NASDAQ:BBLG) Stock Quotes, Forecast and News Summary - Benzinga
Entero Therapeutics appoints new board member - Investing.com
A Look at Entero Therapeutics Inc. (ENTO) Shares in the Recent Past Indicates Growth - SETE News
Enovix Corporation [ENVX] moved down -5.82: Why It’s Important - The DBT News
why Entero Therapeutics Inc. [ENTO] is a Good Choice for Investors After New Price Target of $36.00 - The DBT News
Entero Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
Kraft Heinz Co [KHC] is -7.60% lower this YTD. Is it still time to buy? - The DBT News
For Regions Financial Corp. [RF], Analyst sees a rise to $23. What next? - The DBT News
Market Analysts see HP Inc [HPQ] gaining to $32. Time to buy? - The DBT News
Market Momentum: Entero Therapeutics Inc. (ENTO) Registers a 19.06 Increase, Closing at 0.28 - The Dwinnex
PDD’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
A Tale of Resilience: Entero Therapeutics Inc. Amid Stock Market Turbulence - The InvestChronicle
Company’s Banking Stock: Dissecting a -34.75% Quarterly Revenue Decline Amid Growth - The InvestChronicle
The Psychology of Red Cat Holdings Inc Inc. (RCAT) Price Performance: Understanding Market Sentiment - The InvestChronicle
Energy Transfer LP (ET) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Investing in Entero Therapeutics Inc. (ENTO) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray - RTTNews
Closing Bell Recap: Entero Therapeutics Inc. (ENTO) Ends at 0.24, Reflecting a -61.85 Downturn - The Dwinnex
Arhaus Inc [ARHS] stock Initiated by Stifel analyst, price target now $19.50 - The DBT News
Entero Therapeutics Inc. [ENTO] Revenue clocked in at $0.00 million, down -94.34% YTD: What’s Next? - The DBT News
United States shares higher at close of trade; Dow Jones Industrial Average up 1.76% - Investing.com India
Wall Street Analyst Initiated Celestica, Inc. [CLS]. What else is Wall St. saying - The DBT News
Entero Therapeutics Inc Azioni (ENTO) Dati Finanziari
Non sono disponibili dati finanziari per Entero Therapeutics Inc (ENTO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Entero Therapeutics Inc Azioni (ENTO) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
SAPIRSTEIN JAMES | Chairman and CEO |
Jul 02 '24 |
Sale |
1.07 |
1,289 |
1,379 |
35,816 |
SAPIRSTEIN JAMES | Chairman and CEO |
Apr 01 '24 |
Sale |
4.23 |
174 |
736 |
37,105 |
Romano Sarah | Chief Financial Officer |
Apr 01 '24 |
Sale |
4.23 |
75 |
317 |
19,111 |
SAPIRSTEIN JAMES | Chairman and CEO |
Mar 15 '24 |
Sale |
4.96 |
1,887 |
9,360 |
37,279 |
Romano Sarah | Chief Financial Officer |
Mar 15 '24 |
Sale |
4.96 |
1,120 |
5,555 |
19,186 |
Romano Sarah | Chief Financial Officer |
Jan 12 '24 |
Sale |
4.20 |
98 |
412 |
20,306 |
SAPIRSTEIN JAMES | Chairman, President and CEO |
Jan 12 '24 |
Sale |
4.20 |
166 |
697 |
39,166 |
Romano Sarah | Chief Financial Officer |
Oct 04 '23 |
Sale |
0.29 |
1,676 |
486 |
15,800 |
SAPIRSTEIN JAMES | President and CEO |
Oct 04 '23 |
Sale |
0.29 |
2,764 |
802 |
33,397 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):